DGAP-News: STADA Arzneimittel AG / Key word(s): AGM/EGM
STADA AGM 2011: Executive Board continues to expect further growth in
Group sales and earnings in 2011 and 2012
16.06.2011 / 15:40
---------------------------------------------------------------------
At the Annual General Meeting of STADA Arzneimittel AG, which took place
today, on June 16, 2011, in Frankfurt am Main, the Executive Board, in its
remarks, confirmed the outlook for financial years 2011 and 2012. According
to this outlook, the Executive Board expects further growth in Group sales
and earnings for both years. In its overall assessment, the Executive
Board, from today's perspective, sees the opportunity for an increase in
adjusted EBITDA in the high single-digit percentage range in 2011. This
would mean that adjusted EBITDA in financial year 2011 would reach a record
value in STADA's corporate history.
In the course of the Annual General Meeting, STADA's Chairman of the
Executive Board, Hartmut Retzlaff, in his speech, first addressed the
particular challenges of financial year 2010. In view of the difficult
framework conditions in individual national markets and the burdening
one-time special effects, the Group, in the assessment of the Executive
Board, achieved good operating results in 2010.
In addition to the pleasing development as well as the good prospects in
Russia, Retzlaff then spoke in detail on the achievements already made in
the context of the 'STADA - build the future' cost efficiency program and
on the details of the again accelerated acquisition policy.
In his closing remarks, Retzlaff confirmed that the Executive Board, with a
view to the opportunities and risks facing STADA, and considering the
strategic success factors continues to expect a successful future for the
Group.
The AGM endorsed all proposals of the Executive Board and Supervisory
Board. As a result, a distribution ratio unchanged from the previous year
in the amount of 32% of reported net income and thus a dividend of EUR 0.37
per STADA common share was approved, with the remaining surplus being
carried forward. In addition, the Annual General Meeting confirmed the
Executive Board and the Supervisory Board with almost 100% approval.
Furthermore, the advance resolution on the purchase and use of own shares
as well as the resolution on the approval of the remuneration system for
members of the Executive Board were passed.
The wording of today's speech of STADA's Chairman of the Executive Board
Hartmut Retzlaff as well as the exact voting results for all items on the
agenda can be found at STADA's website at www.stada.com/agm2011.
Additional information:
STADA Arzneimittel AG / Corporate Communications / StadastraÃe 2-18 / D -
61118 Bad Vilbel /
Phone: +49 (0) 6101 603-113 / Fax: +49 (0) 6101 603-506 / E-mail:
communications@stada.de
Or visit us in the Internet at www.stada.com.
End of Corporate News
---------------------------------------------------------------------
16.06.2011 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: STADA Arzneimittel AG
StadastraÃe 2-18
61118 Bad Vilbel
Deutschland
Phone: +49 (0)6101 603- 113
Fax: +49 (0)6101 603- 506
E-mail: communications@stada.de
Internet: www.stada.de
ISIN: DE0007251803, DE0007251845,
WKN: 725180, 725184,
Listed: Regulierter Markt in Düsseldorf, Frankfurt (Prime
Standard); Freiverkehr in Berlin, Hamburg, Hannover,
München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
128523 16.06.2011
DGAP-News: STADA AGM 2011: Executive Board continues to expect further growth in Group sales and earnings in 2011 and 2012
| Source: EQS Group AG